FDG PET is known to have a low sensitivity for the detection of prostate and bladder tumors because of high levels of urinary excretion, which potentially obscures sites of disease. Fluoromethylcholine PET has a higher sensitivity for the detection of metastatic prostate cancer compared with 18F-FDG PET, partly because of lower levels of urinary excretion. We present a case of a patient who underwent 18F-fluoromethylcholine PET for possible recurrent prostate cancer. The study identified an incidental, avid metachronous bladder tumor. We discuss the potential use of fluoromethylcholine PET in the detection of bladder tumors.
From the *Cobalt Health Imaging, Cheltenham, Gloucestershire; and †Worcestershire Royal Hospital Charles Hastings Way, Worcester, United Kingdom.
Received for publication May 10, 2017; revision accepted June 1, 2017.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Amit Parekh, FRCR, Cobalt Health Imaging, Linton House, Thirlestaine Rd, Cheltenham, Gloucestershire GL53 7AS 01242, United Kingdom. E-mail: email@example.com.